Therapeutic management of ocular adnexal MALT lymphoma.
Non-Hodgkin lymphomas constitute 50% of all orbital malignancies. Mucosa-associated lymphoid tissue (MALT)-type lymphoma is the most common histology category in this anatomic region. Ocular adnexal lymphoma of MALT-type is an indolent and rarely lethal malignancy that can often be managed with observation alone. Occasionally, lymphomatous lesions determine the symptoms that condition a patient's quality of life, and so require an immediate antineoplastic treatment. Several strategies are available, but reliable indications supported by prospective trials do not exist. Some therapeutic strategies are associated with substantial side effects and require a well-balanced therapeutic decision, which should take into account several variables related to the patient, the lymphoma, and the treatment itself. In this review, the authors analyze related literature and propose therapeutic guidelines for the management of ocular adnexal lymphoma of MALT-type.
Ferreri
Andres J M
AJ
Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 6020132, Milan, Italy. ferreri.andres@hsr.it
Assanelli
Andrea
A
Crocchiolo
Roberto
R
Dognini
Giuseppina P
GP
Resti
Antonio Giordano
AG
Politi
Letterio S
LS
Doglioni
Claudio
C
Cappio
Federico Caligaris
FC
Dolcetti
Riccardo
R
Ponzoni
Maurilio
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D005134:Eye Neoplasms / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000209:etiology / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents